Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 178INDUSTRY 36OTHER_GOV 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Urogenital Neoplasms 1Thymoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Genital Neoplasms, Female 1Carcinoma, Ovarian Epithelial 1Adrenocortical Carcinoma 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × lenvatinib × Clear all
NCT05036434 2026-01-23

ACCOMPLISH

National Cancer Center, Korea

Phase 2 Active not recruiting
30 enrolled
Endocrine

Adrenocortical Carcinoma

NCT05832827 2023-10-23

Artemis

National Cancer Center, Japan

Phase 2 Recruiting
35 enrolled
Thoracic

Thymoma

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡